Latest Articles about OPTR

Wider-than-Expected Loss at Optimer - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 20:23:36 Z

Optimer Pharmaceuticals Inc. 's ( OPTR ) first quarter 2013 net loss (excluding special items) of 65 cents per share was wider than the Zacks Consensus Estimate of a loss of 42 cents but

Optimer's Dificid Cleared Down Under - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 02:28:01 Z

Optimer Pharmaceuticals ( OPTR ) received encouraging news recently when the Australian regulatory body (Australian Therapeutic Goods Administration) cleared its drug Dificid (fidaxomicin).

1Q Earnings Beat at Cubist Pharma - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 18:14:03 Z

Cubist Pharmaceuticals Inc. 's ( CBST ) first-quarter 2013 earnings (excluding special items) of 34 cents per share beat the Zacks Consensus Estimate by a penny. Earnings were however short

Weekly CEO Sells Highlight: Optimer Pharmaceuticals, ReachLocal, Tractor Supply, and RF Industries

alicet236 — Mon, 15 Apr 2013 03:06:35 Z

According to GuruFocus Insider Data , these are the largest CEO sales of company shares during the past week. Optimer Pharmaceuticals, Inc. ( OPTR ): Former CEO Pedro Lichtinger Sold

Mid-Day Market Update: Delta Tumbles On Weak Forecast, Humana Spikes Higher

Jake L'Ecuyer — Tue, 02 Apr 2013 20:34:37 Z

Midway through trading Tuesday, the Dow traded up 0.64 percent to 14,665.70 while the NASDAQ gained 0.68 percent to 3,261.34. The S&P also rose, gaining 0.61 percent to 1,571.74. Top

Optimer Posts Wider Loss - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 00:55:55 Z

Optimer Pharma 's ( OPTR ) fourth quarter 2012 net loss (excluding special items) of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 38 cents. The company had

Encouraging News for Cubist Pharma - Analyst Blog

Zacks Equity Research — Sat, 02 Mar 2013 03:00:01 Z

Recently, Cubist Pharmaceuticals Inc. ( CBST ) received some encouraging news when the US Food and Drug Administration (FDA) designated its antibiotic candidate CXA-201

Mid-Afternoon Market Update: Dow Heading Toward All-Time High, Accretive Health Gets Blasted

Jake L'Ecuyer — Thu, 28 Feb 2013 01:26:17 Z

Midway through trading Wednesday, the Dow traded up 1.33 percent to 14,084.13 while the NASDAQ rose 1.46 percent to 3,176.08. The S&P also rose, gaining 1.43 percent to 1,518.52. Index

Mid-Day Market Update: Dollar Tree Jumps On Upbeat Profit, First Solar Tumbles

Jake L'Ecuyer — Wed, 27 Feb 2013 23:15:35 Z

Midway through trading Wednesday, the Dow traded up 0.75 percent to 14,004.13 while the NASDAQ rose 1.04 percent to 3,162.08. The S&P also rose, gaining 0.91 percent to 1,510.52. Index

Mid-Morning Market Update: Markets Up; Target Q4 Profit Falls

Jake L'Ecuyer — Wed, 27 Feb 2013 20:49:56 Z

Following the market opening Wednesday, the Dow traded up 0.22 percent to 13,931.00 while the NASDAQ rose 0.27 percent to 3,138.20. The S&P also rose, gaining 0.29 percent to 1,501.26.

Cubist Pharma Inks Deal - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 03:25:01 Z

Cubist Pharmaceuticals Inc. ( CBST ) recently inked an option agreement under which it has the exclusive right to buy the privately-held Adynxx after the data readout of the private

In Line 4Q for Cubist Pharma - Analyst Blog

Zacks Equity Research — Thu, 24 Jan 2013 19:10:01 Z

Cubist Pharmaceuticals Inc. 's ( CBST ) fourth quarter 2012 earnings (excluding special items) of 48 cents per share were in line with the Zacks Consensus Estimate and 20% below the

Optimer's Dificid Sales Look Good - Analyst Blog

Zacks Equity Research — Thu, 10 Jan 2013 04:25:01 Z

Optimer Pharmaceuticals Inc. ( OPTR ) recently announced its preliminary sales for the fourth quarter and full year 2012. Optimer said that preliminary gross product sales of its only

Cubist Reports Impressive 4Q Sales - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 01:43:01 Z

Cubist Pharmaceuticals Inc. 's ( CBST ) unaudited net revenues for the fourth quarter of 2012 climbed 16% year over year to $245.9 million, driven by strong sales of its antibiotic

ALIOF Drug to Move into Phase III - Analyst Blog

Zacks Equity Research — Wed, 26 Dec 2012 23:02:01 Z

Actelion ( ALIOF ) recently announced that it is moving forward with phase III development of cadazolid in patients suffering from clostridium difficile associated diarrhea (CDAD).